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Introduction: Increased expression of αv integrins is frequently associated with tumor cell adhesion, migration,
invasion and metastasis, and correlates with poor prognosis in breast cancer. However, the mechanism by which
αv integrins can enhance breast cancer progression is still largely unclear. The effects of therapeutic targeting of
αv integrins in breast cancer also have yet to be investigated.
Methods: We knocked down αv integrin in MDA-MB-231 and MCF10A-M4 breast cancer cells, or treated these cells with
the αv antagonist GLPG0187. The effects of αv integrin depletion on mesenchymal markers, transforming growth
factor-β (TGF-β)/Smad signaling and TGF-β-induced target gene expression were analyzed in MDA-MB-231 cells
by RNA analysis or Western blotting. The function of αv integrin on breast cancer cell migration was investigated
by transwell assay in vitro, and its effect on breast cancer progression was assessed by both zebrafish and mouse
xenografts in vivo. In the mouse model, GLPG0187 was administered separately, or in combination with the
standard-of-care anti-resorptive agent zoledronate and the chemotherapeutic drug paclitaxel, to study the
effects of combinational treatments on breast cancer metastasis.
Results: Genetic interference and pharmacological targeting of αv integrin with GLPG0187 in different breast
cancer cell lines inhibited invasion and metastasis in the zebrafish or mouse xenograft model. Depletion of αv
integrin in MDA-MB-231 cells inhibited the expression of mesenchymal markers and the TGF-β/Smad response.
TGF-β induced αv integrin mRNA expression and αv integrin was required for TGF-β-induced breast cancer cell
migration. Moreover, treatment of MDA-MB-231 cells with non-peptide RGD antagonist GLPG0187 decreased
TGF-β signaling. In the mouse xenografts GLPG0187 inhibited the progression of bone metastasis. Maximum
efficacy of inhibition of bone metastasis was achieved when GLPG0187 was combined with the standard-of-care
metastatic breast cancer treatments.
Conclusion: These findings show that αv integrin is required for efficient TGF-β/Smad signaling and TGF-β-induced
breast cancer cell migration, and for maintaining a mesenchymal phenotype of the breast cancer cells. Our results also
provide evidence that targeting αv integrin could be an effective therapeutic approach for treatment of breast cancer
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Metastasis is a multi-step process in which cancer cells
disseminate from the primary site to distant tissues or
organs [1]. Breast tumors are commonly epithelial in origin,
and their ability to invade is enhanced by modulators that
stimulate epithelial-mesenchymal transition (EMT), such as
transforming growth factor-β (TGF-β) and transcriptional
repressors Snail, Slug, and Twist that are induced by TGF-
β [2-4]. During the metastasis cascade, (epi)genetic changes
in cancer cells and signals from the microenvironment
promote EMT of the tumor cells in situ, which facilitates
local invasion and intravasation into nearby tissues and
circulation. Subsequently, circulating tumor cells with a
mesenchymal morphology may extravasate out of the blood
stream and invade secondary sites, which involves cell-
matrix interactions [5]. Breast carcinoma cells are able to
infiltrate into specific tissues, including bone, lung and
brain. Within the new microenvironment the tumor cells
start to proliferate, and develop into a macrometastatic
lesion [6].
Integrins are cell-surface adhesion receptors consisting of
α and β transmembrane protein subunits, which directly
interact with extracellular matrix (ECM) components when
regulating cell migration, proliferation, and cell survival via
outside-inside and/or inside-outside signaling mechanisms
[7]. In cancer, integrins contribute to tumor growth,
invasion and metastasis [8]. One of the α integrins, αv, di-
merizes with the β integrin subunits β1, β3, β5, β6 and β8,
and has been implicated in the pathophysiology of malig-
nant tumors [9]. Integrins αvβ3, αvβ5 and αvβ6 have been
reported to be crucial for tumor cell adhesion, migration,
survival, maintenance of stem cell phenotype and angiogen-
esis and for crosstalk with growth factors in the activation
of oncogenes and inhibition of tumor suppressors [10-13].
αv integrin can be involved in activation of latent TGF-β
by binding latency-associated peptide (LAP) [14], can inter-
act with the TGF-β (type II) receptor and thereby promote
TGF-β-induced responses in lung fibroblasts and mam-
mary epithelial cells [15,16], and can interact with the TGF-
β type III receptor endoglin and stimulate TGF-β/Smad
signaling in endothelial cells [17]. Vice versa the TGF-β
receptor can also mediate phosphorylation of certain β-
chains of integrins and modulate their function in hepato-
cellular carcinoma [18]. Moreover, TGF-β can regulate αv
integrin expression in breast epithelial cells and αv integrin
can modulate TGF-β receptor expression in dermal fibro-
blasts [19,20]. Thus, αv integrin and TGF-β signaling show
extensive interplay and αv integrin may be an effector and
mediator of TGF-β signaling responses [21,22].
Human metastatic breast cancer cells residing in bone
showed high αvβ3 integrin expression. The MDA-MB-231
subclone B02, established from bone metastases, was found
to constitutively overexpress αvβ3 integrin compared to the
parental MDA-MB-231 cells [23]. Although αv integrinseems to be an important pharmacological target to in-
hibit breast cancer metastasis, the mechanism by which it
regulates metastatic breast cancer progression is largely
unknown. In this study, selective knockdown of αv integ-
rin expression or pharmacological inhibition of αv integrin
function was found to potently mitigate the invasion and
metastasis of breast cancer cells in zebrafish and mouse
xenograft models. In line with previous studies in other
cell types, mechanistic in vitro studies revealed an inte-
grated interplay between αv integrin and TGF-β, a strong
driver of invasion and metastasis of breast cancer. More-
over, maximum efficacy of bone metastasis inhibition in
mice was accomplished when therapeutic targeting of αv
integrin was combined with standard-of-care metastatic
breast cancer treatments.Methods
Cell culture and reagents
Human MDA-MB-231-luc cells [24] were obtained from
Dr Clemens Löwik (Department of Radiology, Leiden
University Medical Center, Leiden, The Netherlands) and
Dr Gabri van der Pluijm (Department of Urology, Leiden
University Medical Center, Leiden, The Netherlands). The
MDA-231/B02-luc line was previously published [23] and
used for mouse xenograft experiments. These MDA-
MB-231 cell lines were maintained at 37°C in DMEM high
glucose containing L-glutamine, 10% FBS and 100 U/ml
Pen/Strep (Gibco, Invitrogen, Blijswijk, Netherlands).
MCF10A-M4 cells were kindly provided by Dr Fred Miller
(Barbara Ann Karmanos Cancer Institute, Detroit, USA)
and maintained at 37°C in DMEM/F12 (Gibco, Invitrogen,
Blijswijk, Netherlands) containing 5% horse serum (Gibco,
Invitrogen, Blijswijk, Netherlands), 0.1 μg/ml cholera toxin
(Merck Millipore, Amsterdam, Netherlands), 0.02 μg/ml
epidermal growth factor (EGF), 0.5 μg/ml hydrocorti-
sone (Sigma, Zwijndrecht, Netherlands), 10 μg/ml
insulin (Sigma, Zwijndrecht, Netherlands), 50 μg/ml
streptomycin, and 100 U/ml Pen/Strep (Gibco, Invitrogen,
Blijswijk, Netherlands).Zebrafish embryo production and tumor cell injection
The transgenic zebrafish line Tg(fli1:GFP) was raised,
staged and maintained according to standard procedures
in compliance with the local Institutional Committee for
Animal Welfare of the Leiden University Medical Center
(LUMC). Tumor cell injection into zebrafish embryos was
conducted as we previously described [24]. Briefly, ap-
proximately 400 fluorescent-labeled mammalian cells were
injected into the duct of Cuvier (DoC). After implantation,
zebrafish embryos (including non-implanted controls)
were maintained at 33°C [25]. For each cell line or condi-
tion, data are representative of at least two independent
experiments with at least 50 embryos per group.
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GLP0187 (Galapagos NV, Mechelen, Belgium) was added
to the zebrafish egg water 2 days post fertilization (dpf)
for toxicity tests, or 2 days post implantation (dpi) for
treatment, and refreshed every second day. For toxicity
tests, embryo survival or malformation was scored daily.
For GLPG0187 treatment, after 5 days embryos were
fixed overnight in 4% buffered paraformaldehyde at 4°C.
Embryos were placed in a glass-bottom 96-well plate
(Greiner Bio One GmbH, Frickenhausen, Germany),
and imaged as described.
Lentiviral transduction
Lentivirus was produced by co-transfecting pLKO-1
(shRNA-knockdown) plasmids and helper plasmids
pCMV-VSVG, pMDLg-RRE (gag/pol), and pRSV-REV into
HEK293T cells. Cell supernatants were harvested 48 h after
transfection and used to infect cells or stored at −80°C.
pLKO-1 plasmids with specific shRNAs were obtained from
Sigma, Zwijndrecht, Netherlands (MISSION® shRNA). We
used TRCN-0000003240 and TRCN-0000010769 for αv
integrin knockdown. For stable cell lines, cells were infected
at 20% confluence for 24 h with lentiviral supernatants
diluted 1:1 with normal culture medium in the presence of
8 μg/ml polybrene (Sigma, Zwijndrecht, Netherlands): 24 h
after infection, cells were placed under puromycin (1 μg/ml)
selection for 3 days or more.
Fluorescence-activated cell sorting (FACS) analysis
Cells were washed once with PBS and harvested with
0.05% trypsin/0.025% EDTA. Detached cells were washed
with EDTA, re-suspended in EDTA (4 × 104/ml), and Fc-
blocked for 15 minutes at room temperature. Anti-human
αv integrin conjugated to Phycoerythrin (PE) (R&D sys-
tems, Abingdon, UK) was added and cells were incubated
for 45 minutes at 4°C. PE-conjugated mouse IgG anti body
(R&D systems, Abingdon, UK) was used as a negative
control. Cells were washed three times in PBS and PE
fluorescence was measured on a BD LSR II Cytometer.
Results were analyzed with BD FACS Diva 6.1 software.
Apoptosis assay
The apoptotic effects of αv integrin were examined using
propidium iodide (PI) flow cytometry as previously de-
scribed [26]. Detached and adherent cells were collected
and labeled for 15 minutes at room temperature with PI
(40 μg/ml) and immediately analyzed on a BD LSRII flow
cytometer (BD Biosciences, Breda, Netherlands) using BD
FACS Diva6.1 software.
RNA isolation and real-time quantitative PCR (RT-PCR)
RNA was extracted with a NucleoSpin RNA II kit (BIOKE,
Leiden, Netherlands) according to the supplier’s manual.
For RT-PCR a RevertAid First Strand cDNA Synthesis Kit(Thermo Scientific, Leusden, Netherlands) was used. RT-
PCR was performed on a CFX connect real-time PCR sys-
tem (Bio-Rad, Veenendaal, Netherlands) and analyzed with
CFX Manager software version 2.0 (Bio-Rad, Veenendaal,
Netherlands). The sequences of the primers are given in
the supplemental information. All samples were analyzed
in triplicate and normalized to GAPDH.
The sequences of the primers were as follows: Integ-
rin αv forward: 5′-CTTCTTGGTGGTCCTGGTAGG-3′;
Integrin αv reverse: 5′-TTTCTGCCACTTGATCCGA
AA-3′; GAPDH forward: 5′-AGCCACATCGCTCAG
ACA C-3′; GAPDH reverse: 5′-GCCCAATACGACCA
AATC C-3′; N-cadherin forward: 5′-CAGACCGACCC
AAACAGCAAC-3′; N-cadherin reverse: 5′-GCAGCA
ACAGTAAGGACAAACATC-3′;Snail forward: 5′-AC
CACTATGCCGCGCTCTT-3′; Snail reverse: 5′-GGT
CGTAGGGCTGCTGGAA-3′; Slug forward: 5′-ATG
AGGAATCTGGCTGCTGT-3′; Slug reverse: 5′-GAGGA
GAAAATGCCTTTGGA-3′; Vimentin forward: 5′-CCA






forward: 5′- GCAGGACATCCGGGAGAGA-3′; PAI-1
reverse: 5′-CCTGAGAACCTCCCTTGACCTT-3′.
Western blot analysis
Western blotting was carried out as previously described
[27]. The primary antibodies used were anti-N-Cadherin
(BD Biosciences, Breda, Netherlands #610920), anti-α-
Smooth Muscle Actin (Sigma, Zwijndrecht, Netherlands
#A2547), anti-Snail (Cell Signaling, Leiden, Netherlands
#3879), anti-Smad2 (BD Biosciences, Breda, Netherlands
#610842), anti-p-Smad2 (Cell Signaling, Leiden, Netherlands
#3108), anti-Smad4 (Santa Cruz #sc7966), anti-TGFβRI
(Santa Cruz, Heidelberg, Germany #sc 398), anti-TGFβRII
(Santa Cruz, Heidelberg, Germany #sc-400), anti-Smad3
(Epitomics, Duiven, Netherlands #1735–1), anti-p-Smad3
(a kind gift from Dr Edward B Leof, Mayo Clinic, Rochester,
Minnesota) and anti-β-actin (Sigma, Zwijndrecht, Netherlands
#A5441). All the secondary antibodies were from Sigma,
Zwijndrecht, Netherlands. Western quantification was
performed using image J software.
Transwell migration assay
Migration assays were performed in 24-well polyethylene
terephthalate inserts (Corning Life Sciences, Amsterdam,
Netherlands, 8.0- μm pore size): 1 × 104 MDA-MB-231
cells were cultured in DMEM with 0.5% FBS and seeded
in the upper compartment (replicas for each sample).
Then the cells were treated with or without TGF-β3
(5 ng/ml) for 16 h, which allows cells to migrate to the
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the filter membrane were removed with a cotton swab.
Cells on the lower side of the filter were fixed in 4%
paraformaldehyde, stained with crystal violet 0.5% and
then counted and photographed by randomly choosing
different views under the microscope.
Animals and surgical procedures
Four- to five-week-old female Balb-c nu/nu mice (Charles
River, les Oncins, France) were anesthetized with isofluor-
ane and 5 × 105 freshly harvested MDA-MB-231/B02 luc
cells in 100 μl PBS were inoculated into the tail vein [28].
All mouse experiments were performed according to eth-
ical guidelines edited by the Animal Institutional Care
and Use Committee of Galapagos controlled by French
Authorities (agreement number B 93 063 06, DDPP, Seine
Saint Denis, France). The Comité National de Rélexion
Ethique sur l’Expérimentaion Animale approved all the
mice experiments for this study on 5 July 2012. All
research using zebrafish, including housing and expe-
riments, was carried out according to the international
guidelines and approved by the local Institutional
Committee for Animal Welfare (Dier Ethische Commissie
(DEC) of the LUMC.
Proliferation assay in vitro
MDA-MB-231 or MCF10A-M4 cells were seeded at
2,000 cells per well in a 24-well plate. GLPG 0187 treat-
ment was started 12 h after seeding. The numbers of
cells were counted each 36 or 24 h until 108 or 96 h
after seeding. Each experiment was performed in tripli-
cates and numbers were calculated with a T20 cell coun-
ter (Brio-Rad, Veenendaal, Netherlands).
Proliferation assay in zebrafish
Approximately 70 mCherry-labeled MDA-MB-231 cells
were injected in to the yolk sac of 2-dpf fli1:GFP Casper
zebrafish embryos. Embryos were sorted 1 day post in-
jection (dpi) by confocal microscopy to assess the fluor-
escent mass at the yolk sac and the images were scanned
by z-stacks. Injected embryos were kept in 96-well plates
at 33°C and scanned at 6 dpi. The relative volume of
tumor cells was calculated by Stacks software.
Immunoflurescence staining in zebrafish
Xenografted zebrafish embryos were fixed with 4% parafor-
maldehyde. Samples were first dehydrated with methanol
followed by a rehydration step and treated with 10 ug/ml
proteinase K for 10 minutes at 37°C. Then cells were
blocked and permeabilized with 1% BSA and 0.5% Triton
X-100 in PBS before incubation with primary antibody Ki
67 (Merck Millipore, Amsterdam, Netherlands #AB9260;
1:200 in blocking buffer) in 4°C for 12 h. Samples then
were washed with 5% Triton X-100-PBS, incubated withdonkey anti rabbit IgG Alexa Fluor 647 (Invitrogene
#A31572 1:200 in blocking buffer) at room temperature for
2 h. After washing with PBS, the embryos were analyzed
the using confocal microscope SP5 STED (Leica, Rijswijk,
Netherlands).
In vivo imaging and radiography
Metastatic tumor growth was followed weekly by bio-
luminescence imaging (BLI) with the NightOwl, (Berthold,
Bad Wildbad, Germany). The BLI signal intensity was
quantified as the sum of photons within a region of inter-
est given as the total flux (photons/second).
Statistical analysis
Statistical analysis was performed using Prism 4 software
(GraphPad La Jolla, USA). Results are expressed as the
mean ± SD. Two-way analysis of variance (ANOVA)
followed by the two-tailed Student t-test were used.
P <0.05 was considered to be statistically significant
(*0.01 < P <0.05; **0.001 < P <0.01; *** P <0.001).
Results
Establishment of stable αv integrin knockdown in
MDA-MB-231 cells
Analysis of Oncomine™ gene expression data [29] revealed
that αv integrin is significantly upregulated in ductal breast
carcinoma in situ epithelia or invasive ductal breast carcin-
oma epithelia (Figure 1A). Using publicly available data-
bases we also found that αv integrin is highly expressed in
breast cancer and that its expression was found to correlate
with poor prognosis in 2,960 patients (Figure 1B) [30]. To
further explore the expression of αv integrin in breast can-
cer cells, we analyzed αv integrin mRNA levels in breast
cancer cell lines of different molecular subtypes by using a
published dataset [31]. Integrin αv expression was higher in
basal-like breast cancer cells, including MDA-MB-231 and
MCF10A cell lines, than in luminal cell lines (Figure 1C).
Moreover, the more aggressive MDA-MB-231 cells
expressed more αv integrin than MCF10A-M4 (in short,
M4) cells (Additional file 1: Figure S1A).
Next we performed loss of function analysis of αv in-
tegrin in basal-like breast cancer lines. Two independent
stable MDA-MB-231 cell lines were generated in which
αv integrin was knocked down using distinct shRNA
targeting sequences. The knockdown efficiency was ex-
amined by FACS and Real-time qPCR analysis (Figure 1D
and E). The cell surface protein and mRNA levels of αv
integrin were significantly decreased upon shRNA-
mediated depletion.
Previous studies showed that several integrins can
affect cell survival [32]. We therefore tested whether αv
integrin knockdown increased the amount of apoptotic
MDA-MB-231 cells. After 7 days of infection, the per-
centage of sub G1 cells was 6% and 5% for the two
Figure 1 Knockdown of αv integrin in breast cancer cells. (A) Oncomine™ box plots of αv expression levels in normal breast and breast
cancer data [29]. Normal versus ductal breast carcinoma in situ epithelia, P = 0.04; Normal versus invasive ductal breast carcinoma epithelia,
P = 0.02. (B) Kaplan-Meier curves for the overall survival of breast carcinoma patients with high and low αv integrin expression; data obtained from
the Kaplan-Meier plotter database [30]. P-values were calculated by log-rank test. (C) mRNA expression profile of αv integrin in breast cancer cell
lines of different molecular subtypes (basal A, basal B and luminal) [31]. (D) FACS analysis of the αv integrin protein levels on the surface of
control and αv integrin knockdown MDA-MB-231 cells, generated by stable infection with lentiviral vectors expressing two independent αv integrin
targeting short hairpins (KD 1 and KD 2) or a control short hairpin (Co. sh). The percentage of αv+ cells was analyzed by flow cytometry. (E) Real-time
quantitative PCR detection of αv integrin mRNA levels in control and αv integrin knockdown MDA-MB-231 cells. All samples were analyzed in triplicate
and normalized to GAPDH (P <0.001). (F) Left, representative FACS profiles of propidium iodine (PI)-stained control MDA-MB-231 cells, αv knockdown
cells and doxorubicin-treated MDA-MB-231 cells, a positive control (Co. Pos) for apoptosis detection. P2: subG1 cells. Right, percentage of sub G1 cells
calculated by FACS. Co. Pos versus Co.sh or αv KD cells: P <0.01. Average ± SD of three independent experiments.
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ing the control shRNA contained 6% sub G1 cells. In
contrast, cells treated with 1 μg/ml doxorubicin for 48 h
as a positive control for apoptotic response contained
33% sub G1 cells (Figure 1F). Taken together, the
shRNAs used efficiently target αv integrin in MDA-MB-
231 cells and have no adverse effects on cell survival at
the experimental conditions we investigated.αv integrin knockdown inhibits tumor invasion and
metastasis in a zebrafish model
Next we investigated the role of αv integrin in breast cancer
metastasis using a zebrafish xenograft model [33]. In a pre-
vious study it was reported that circulating cancer cells do
not proliferate before colonization at the secondary site
when examined in zebrafish embryos; phosphohistone-H3
postive tumor cells could only be detected after micro-
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knockdown on MDA-MB-231 proliferation in the primary
xenotransplant site in embryonic zebrafish - the yolk sac.
Additional file 1: Figure S1B shows the location of cells at 1
dpi, as well as the location (after migration) of cells at 6 dpi.
The cells did not proliferate rapidly in vivo and the volume
of shRNA control MDA-MB-231 cells is not significantly
higher than the volume of αv integrin knockdown MDA-
MB-231 cells at 6 dpi (Additional file 1: Figure S1C). To
determine the percentage of breast cancer cells undergoing
proliferation, we performed whole mount zebrafish immu-
nostaining to examine Ki67 (a proliferation marker) expres-
sion in the transplanted cells (Additional file 1: Figure
S1D). Both of the αv integrin knockdown cells and the
control cells displayed approximately 65% proliferating
cells. This suggests that knockdown of αv integrin does
not significantly affect cell proliferation in vivo during
the 6 day time period of the zebrafish xenograft assay.
Zebrafish provide an important xenograft model for in-
vestigation of both tumor migration, angiogenesis and
progression [34]. We previously showed that human breast
cancer cells injected into the Duct of Cuvier (DoC) of zeb-
rafish embryos will immediately disseminate throughout
the circulatory system of the embryo, and during the next
6 days are capable of invading into the tail fin (3–30 cells),
and forming micrometastasis (>30 cells) [35]. The fluores-
cently labeled αv integrin knockdown and control shRNA
infected MDA-MB-231 cell lines were transplanted into
the DoC of 48 hpf (hours post-fertilization) zebrafish em-
bryos to study invasion and micrometastasis behavior
in vivo (Figure 2A). We observed a dramatic decrease of
invasion and micrometastasis in the MDA-MB-231 cells
upon αv integrin knockdown (Figure 2B). Whereas control
cells invaded into the avascular tail fin in 53% of zebrafish
embryos, knockdown of αv integrin reduced the number
of embryos displaying invasion to 30% with shRNA1, and
32% with shRNA2 (Figure 2C). Detailed pictures displayed
the invading cells located into the collagen fibers of the tail
fin in the control group, which is not seen in the αv integ-
rin KD groups (Figure 2D). A significant reduction of the
invasive area in each embryo was also detected in αv integ-
rin KD groups (Figure 2E). Moreover, we consolidated
these results with siRNA targeting αv integrin, which also
reduced tumor invasion and micrometastasis in the zebra-
fish embryo (Additional file 2: Figure S2A, B and C).
To substantiate these results, we also examined the effect
of αv integrin knockdown in MCF10A-M4 breast cancer
cells. Stable αv integrin knockdown MCF10A-M4 cell lines
were established by lentiviral shRNA infection (Additional
file 3: Figure S3A-D). Unlike MDA-MB-231 cells, which
migrate out as single cells into the avascular tail fin area,
extravasated MCF10A-M4 cells invaded and formed a
cluster of cells into the caudal hematopoietic tissue (CHT)
between the dorsal aorta and caudal vein (Figure 2F, upperpanel) [36]. Also, in this case, αv integrin knockdown
significantly reduced breast cancer cell invasion and micro-
metastasis in the tail fin of zebrafish embryos (Figure 2F,
lower panel). Although 61% of zebrafish embryos xeno-
transplanted with control shRNA expressing MCF10A-M4
cells displayed invasion/micrometastasis, upon αv integrin
knockdown only 37% and 42% of the zebrafish embryos dis-
played invasion/micrometastasis (two independent shRNAs)
(Figure 2G and H). Moreover, the invasive area of breast
cancer cells was also decreased for the αv integrin KD cells
(Figure 2I). These data indicate that αv integrin can pro-
mote breast cancer metastasis in multiple cell types and
conditions.
αv integrin is required for multiple mesenchymal features
of MDA-MB-231 cells
The acquisition of mesenchymal properties is critical for
early-stage carcinoma to switch to invasive malignancy,
which is often associated with epithelial-mesenchymal tran-
sition (EMT), loss of epithelial differentiation and gain of a
mesenchymal phenotype [37]. Therefore, we tested the
effect of αv integrin on the expression of mesenchymal
markers in MDA-MB-231 cells, which is a motile, highly
aggressive and invasive cell line, and contains a typical
mesenchymal morphology. mRNA analysis showed that
knockdown of αv integrin resulted in a consistent decrease
of Snail, Slug, N-Cadherin, and Vimentin mRNA levels
(Figure 3A). Western blotting also showed significant re-
duction of N-cadherin, α-smooth muscle actin and Snail
protein in αv integrin knockdown cells (Figure 3B).
siRNA-mediated depletion of αv integrin caused reduced
expression of mesenchymal markers as well (Additional
file 4: Figure S4A). Knockdown of αv integrin in
MCF10A-M4 also significantly decreased Snail expression
(Additional file 4: Figure S4B). Depletion of αv integrin in
MDA-MB-231 cells did not affect E-Cadherin protein
levels (data not shown). These data indicate that in MDA-
MB-231 cells αv integrin is required for the expression of
various mesenchymal markers that are important for ac-
quisition of an aggressive and metastatic phenotype.
By analyzing the mRNA expression profiles of a publicly
available dataset of a panel of breast cancer cell lines, we
found that high expression of αv integrin positively corre-
lates with expression of the mesenchymal markers Slug,
N-Cadherin and Vimentin (Figure 3C) [31]. Moreover, to
investigate the relationship between αv integrin and mes-
enchymal marker expression in breast cancer patients, we
analyzed the expression of αv integrin, Slug and Vimentin
in the Gene Expression Omnibus (GEO) database [GEO:
GSE9309] and observed that αv integrin expression posi-
tively has been found to correlate with Slug and Vimentin
expression in 142 breast cancer patients (Figure 3D). Ana-
lysis of Oncomine™ gene expression data (TCGA database
[38]) showed that both αv integrin and Snail mRNA are
Figure 2 (See legend on next page.)
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Figure 2 Integrin αv is required for tumor cell invasion and metastasis in xenografted zebrafish. (A) Schematic diagram of the zebrafish
embryo xenograft model. (B) mCherry-labeled MDA-MB-231 cells infected with control shRNA (Co. sh) or αv integrin knockdown shRNAs (KD 1 and KD
2) were injected into zebrafish at 48 hours post fertilization (hpf). Confocal images were made 6 days post implantion (dpi). Arrows indicate invasive
tumor cells, scale bar: 500 μm. (C) Percentage of embryos displaying invasion and metastasis detected at day 6 post injection. Data ± SD are
representative of three independent experiments (each, n >50). Control versus αv KD 1 P <0.01; control versus αv KD 2 P <0.001. (D) High-
resolution images of tumor cells in the posterior tail fin (upper panel, fluorescence; lower panel, transmitted). Arrows indicate invasive tumor cells, scale
bar: 100 μm. (E) Area of invasive cells in each embryo (n = 18). Control versus αv KD 1 P <0.01; control versus αv integrin KD 2 P <0.05. (F) Invasion and
metastasis in zebrafish xenografted with control or αv integrin knocked-down MCF10A-M4 cells at 6 dpi. Arrows indicate invasive tumor cells, scale bar:
500 μm. (G) Percentage of embryos displaying invasion and metastasis detected at day 6 post-injection. Control versus αv KD 1 P <0.01; control versus
αv KD 2 P <0.01. (H) High-resolution images of tumor cells in the posterior tail fin (upper panel, fluorescence; lower panel, transmitted). Arrows indicate
invasive tumor cells, scale bar: 100 μm. (I) Area of metastatic clusters in each embryo (n = 30). Control versus αv KD 1 P <0.01; control versus αv KD 2
P <0.001.
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4: Figure S4C). Together, these results illustrate that αv in-
tegrin expression correlates with mesenchymal character-
istics in metastatic breast cancer cells.
αv integrin-TGF-β interplay in MDA-MB-231 breast
cancer cells
TGF-β plays a critical role during breast cancer metastasis,
and also has been reported to stimulate αv integrin ex-
pression in certain cell types [15,19]. In addition, αv integ-
rin may have an effector role in TGF-β-induced cell
migration [19]. Therefore, we investigated the αv integrin-
TGF-β interplay in MDA-MB-231 breast cancer cells.
TGF-β treatment induced αv integrin mRNA expression
at 6 and 20 h (Figure 4A), and depletion of αv integrin re-
duced both basal and TGF-β-induced MDA-MB-231 mi-
gration in a transwell assay (Figure 4B).
Next we investigated the role of αv integrin in TGF-β
signaling using phosphorylation of its downstream effec-
tors Smad2 and Smad3 as read-out. Upon knockdown of
αv integrin in MDA-MB-231 cells, both TGF-β-induced
Smad2 and Smad3 phosphorylation (as well as TGF-β-
induced p38 MAP kinase) were significantly inhibited
(Figure 4C and Additional file 5: Figure S5A). The total
levels of Smad2, Smad3, Smad4 and TGFβ receptors
remained unaltered (Additional file 5: Figure S5B). More-
over, the TGF-β-induced Smad3/Smad4-driven transcrip-
tional response was mitigated upon depletion of αv
integrin in 293 T cells (Additional file 5: Figure S5C). These
results are consistent with previous data obtained in glio-
blastoma cells [39]. Subsequently, the effect of αv integrin
depletion on TGF-β- induced target gene expression in
MDA-MB-231 cells was analyzed. Figure 4D shows that
TGF-β induction of PAI-1, CTGF and IL-11 was signifi-
cantly decreased in the αv integrin knockdown cells. In line
with the reduction in basal phosphorylation of Smad2 and
Smad3, the basal expression of PAI-1 and CTGF was also
affected upon αv integrin knockdown (Figure 4D). Collect-
ively, these results revealed that αv integrin is a target of
TGF-β, needed for efficient TGF-β/Smad signaling, and
required for TGF-β-induced cell migration.Therapeutic targeting of αv integrin by GLPG0187
antagonises breast cancer metastasis in a zebrafish model
GLPG0187 is a recently developed non-peptide RGD
antagonist, which inhibits αv integrin-ligand interactions
[19,40]. More specifically, this small molecule compound
was found to exhibit high affinity for αvβ1, αvβ3, αvβ5,
αvβ6, αvβ8 as well as α5β1 in in vitro competitive binding
assays [19]. The impact of GLPG0187 on cell prolifera-
tion/viability was evaluated by cell counting. Treatment
of MDA-MB-231 cells with 0.5 or 1 ng/ml GLPG0187
did not change the rate of proliferation significantly
(Additional file 5: Figure S5D). Next we examined whether
GLPG0187 affects TGF-β signaling in MDA-MB-231 cells.
GLPG0187 treatment attenuated TGF-β-induced phos-
phorylation of Smad2 and Smad3 in a dose-dependent
manner (Figure 5A). In addition, we observed that
GLPG0187 dose-dependently inhibited TGF-β-induced
PAI-1, CTGF and IL-11 mRNA expression in MDA-
MB-231 cells (Figure 5B). Taken together these results
indicate that αv integrin-inhibition by GLPG0187, as
with genetic depletion of αv integrin mitigates TGF-β
signaling.
To test the potential therapeutic advantage of αv in-
tegrin targeting, MDA-MB-231 breast cancer cells were
pretreated for 6 h with 1 ng/ml GLPG0187. Cells were
subsequently xenotransplated into 48-hpf Fli:GFP zebra-
fish embryos, and 0.5 ng/ml GLPG0187 (a dose at which
no toxicity was observed in zebrafish embryos) was
added to the water every second day after injection. As a
result, the embryos transplanted with MDA-MB-231
cells treated with the vehicle developed an aggressive
tumor lesion on the tail fin in 56% of the embryos. In
contrast, pretreatment of MDA-MB 231 cells with
GLPG0187 (1 ng/ml) for 6 h before injection and treat-
ment of zebrafish embryos with GLPG0187 (0.5 ng/ml)
after injection caused a significant reduction of tumor
cell invasion (16%) (Figure 5C,D and E). GLPG0187 also
inhibited the invasion of MCF10A-M4 cells in zebrafish
embryos (data not shown). These data show that
GLPG0187 blocks breast cancer invasion, and subse-
quent micrometastasis in this zebrafish model.
Figure 3 Integrin αv regulates mesenchymal gene expression. (A) Real-time qPCR mRNA analysis of various mesenchymal genes in MDA-MB-231
cells infected with control shRNA (Co. sh) or αv integrin knockdown shRNAs (KD 1 and KD 2). The RNA levels (± SD) of αv integrin, N-Cadherin, Slug, Snail
and Vimentin are normalized to GAPDH expression. (B) Left, immunoblot detection of N-cadherin, Snail and α-smooth muscle actin protein in the cells
shown in panel A. Right, quantification of the protein levels: three independent experiments, average ± SD. (C) αv integrin mRNA expression positively
correlates with the mesenchymal markers N-Cadherin, Slug and Vimentin in a large breast cancer cell line dataset [31]. Pearsons’ coefficient tests were
performed to assess statistical significance. (D) Scatter plots showing positive correlations between αv integrin, Slug and Vimentin expression in breast
cancer patients using the Gene Expression Omnibus (GEO) [GEO:GSE9309]. Pearsons’ coefficient tests were performed to assess statistical significance.
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metastasis
According to the previous zebrafish results, GLPG0187
shows potent anti-tumor progression activities. A
phase-I trial in healthy volunteers with GLPG0187 has
started (ClinicalTrials.gov Identifier: NCT01313598,
NCT01580644, NCT00928343). To further confirm anti-
metastatic activity of GLPG0187 we performed xenograft
experiments in a mouse model of female nude mice that
were intravenously injected with MDA-MB-231/BO2 cells,
a subclone of MDA-MB-231 that stably expressesluciferase, and which selectively metastasizes to bone [23].
First detection of metastatic cells in bone by lumines-
cence was possible at day 13, which allowed
randomization. At the day following randomization,
mice were treated with vehicle or GLPG0187 weekly to
evaluate whether GLPG0187 can inhibit established
metastases. Forty-two days after injection, mice treated
only with vehicle displayed aggressive bone metastases
that developed continuously, whereas mice treated with
GLPG0187 only developed tiny detectable metastases in
bone (Figure 6A). Compared with the vehicle-only group,
Figure 4 αv integrin and transforming growth factor (TGF)-β signaling interaction in breast cancer progression. (A) MDA-MB-231 cells
were cultured with or without TGF-β for the indicated times, and RNA was isolated for αv integrin expression analysis by qRT-PCR. (B) Left, transwell
assay. Control and knockdown MDA-MB-231 cells were treated with or without 5 ng/ml TGF-β for 16 h and migrated cells were stained. Right, average
cell numbers of migrated cells ± SD. (C) Immunoblot analysis of phosphorylated Smad2 and Smad3 (p-Smad2 and 3) and total Smad2 and 3 in control
or αv integrin knockdown MDA-MB-231 cells. Cells were treated with or without 5 ng/ml TGF-β for 2 h. (D) Knockdown of αv integrin in MDA-MB-231
cells inhibits expression of TGF-β target genes upon 6 h TGF-β treatment. mRNA levels of PAI-1, CTGF, and IL-11 were assessed by real-time quantitative
PCR, and normalized to GAPDH expression.
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treated with GLPG0187 42 days after injection (Figure 6B).
These results suggest that GLPG0187 reduces the osteo-
lytic bone-metastatic ability of MDA-MB-231 cells.
GLPG0187 achieves maximum efficacy when combined
with standard-of-care metastatic breast cancer treatments
Next we studied the anti-metastatic activities of GLPG0187
in combination with standard-of-care treatments for meta-
static breast cancer with the aim of checking the potential
antagonistic effects of these treatments in a mouse model.
The results showed that GLPG0187 treatment exerted an
anti-metastatic effect when MDA-MB-231 cells metasta-
sized to bone. Importantly, combinations of GLPG0187
with the antiresorptive agent zoledronate showed superior
activity on both tumor burden and the associated osteolytic
lesions compared to each treatment separately (Figure 7A
and B). We observed up to 84% inhibition of the tumor
burden and full bone protection against osteolysis, asmeasured by bone volume, compared to intact control
mice (Figure 7C). When GLPG0187 was combined
with the chemotherapeutic drug paclitaxel, the forma-
tion of the tumor burden and tumor-induced osteolysis
were dramatically decreased in comparison with the
other treatment (Figure 7D and E). Also, a diminished
tumor burden in tibiae was achieved with combination
treatment (Figure 7F). In addition to the absence of an
antagonistic effect, the combination of GLPG0187 with
approved antiresorptive or chemotherapeutic agents
shows superior efficacy when compared to each treat-
ment taken separately.
Discussion
Studies correlating integrin expression levels in human tu-
mors with pathological outcome, such as patient survival
and metastasis have identified several integrins that might
have an important role in cancer progression. Here we in-
vestigated the role of αv integrin in breast cancer invasion
Figure 5 GLPG0187 suppresses breast tumor invasion and metastasis in zebrafish. (A) MDA-MB-231 cells were treated with vehicle, 0.5 ng/ml
or 1 ng/ml of GLPG0187 for 48 h with or without 5 ng/ml transforming growth factor (TGF)-β for 2 h and immunoblotted as shown. (B) MDA-MB-231 cells
were treated with vehicle, 0.5 ng/ml or 1 ng/ml of GLPG0187 for 48 h with or without 5 ng/ml TGF-β for 6 h and subjected to quantitative PCR analysis.
mRNA levels of PAI-1, CTGF, and IL-11 were normalized to GAPDH expression. (C) MDA-MB-231 cells were pretreated for 6 h with 1 ng/ml GLPG0187 or
vehicle, then injected into the blood circulation of zebrafish 48-h post fertilization and followed with or without 0.5 ng/ml GLPG0187
treatment, as indicated. Confocal images of overview zebrafish were made 5 days post implantion (dpi). Arrows indicate invasive tumor
cells, scale bar: 500 μm. (D) Percentage of embryos displaying invasion and metastasis at 1, 3, and 5 dpi is shown; vehicle versus GLPG0187
P <0.001. (E) Representative images of the zebrafish described in panel D. Experimental micrometastasis was detected in the posterior tail
fin at 5 dpi. Arrows indicate invasive tumor cells, scale bar: 100 μm.
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Figure 6 GLPG0187 inhibits progression of established bone metastasis. (A) Bioluminescent imaging at week 6 of two representative mice
injected with MDA-MB-231 cells and administered with vehicle or GLPG0187 (100 mg/kg) weekly. (B) Representative radiographic images illustrating
GLPG0187 (100 mg/kg) efficacy on associated osteolytic lesions in this mouse model of human breast cancer bone metastasis.
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breast cancer. Selective shRNA-mediated knockdown of
αv integrin expression was found to potently mitigate in-
vasion and metastasis of breast cancer cells in zebrafish
and mouse xenograft models. This study further estab-
lished the zebrafish embryo xenograft model as a robust
and dependable animal model for cancer research. Trans-
planted fluorescently labeled mammalian tumor cells in
zebrafish can survive, invade and metastasize, and thus
display similar behavior to cells transplanted in the trad-
itional mammalian models [41]. Moreover, the zebrafish
embryo model also enables us to monitor the metastasis
cascade at the single-cell level.
Metastasis is associated with acquisition of mesenchy-
mal characteristics. Here we explored the impact of αv in-
tegrin on maintenance of mesenchymal morphology in
mammary carcinoma. Reduced expression of αv integrin
in MDA-MB-231 cells was associated with downregula-
tion of mesenchymal effectors. Moreover, αv integrin was
upregulated by TGF-β and found to participate in stimula-
tion of TGF-β-induced cell migration, TGF-β-target gene
activation, and TGF-β/Smad signaling. This is in line
with previous studies showing that various integrins can
stimulate TGF-β-induced signaling at multiple levels
[14,21,22,42,43].
Whether the reduction in basal migration, basal phos-
phorylation of Smad2 and basal expression of PAI1 and
CTGF after αv integrin knockdown is caused by reduction
of integrin-mediated activation of latent TGF-β, or by
interference with autocrine active TGF-β-like signalingremains to be established. Irrespective of the exact mech-
anism, our results indicate that αv integrin at least in part
mediates TGF-β/Smad signaling, which has been shown
to be critical for the bone metastasis signature of MDA-
MB-231 cells [44,45]. This notion is consistent with pre-
vious observations that interfering with TGF-β signaling
inhibits integrin expression and TGF-β-induced metastasis
of breast cancer cells [46], and that expression of αvβ3
integrin is a key determinant for homing of breast cancer
cells to bone [47]. In addition, αv integrin will also have
functions that are independent of TGF-β, such as outside-
in and inside-out signaling, which may also be important
for invasive and metastatic properties of breast cancer
cells [21]. In the bone metastatic lesions, integrins are
essential for the interaction between tumor cells and
ECM, and also play a role in osteoclast-bone binding [48].
For example, αvβ3 has high affinity binding with the bone
marrow stroma ligands, osteopontin and vitronectin, to
promote prostate bone metastasis [49].
Interestingly, analysis of a previously published data-
set, in which 52 breast cancer cell lines were transcrip-
tionally profiled [31], revealed significant correlation
between expression of αv integrin and the mesenchymal
markers N-Cadherin, Slug and Vimentin. Moreover, αv
integrin was found to be highly expressed in mesenchy-
mal breast cancer, with an invasive and metastatic pheno-
type. A previous study revealed that BMP7 may inhibit
TGF-β-induced EMT and bone metastasis in both breast
and prostate cancer by decreasing αvβ3 integrin expres-
sion [19,50]. Moreover, antibody-mediated blockade of αv
Figure 7 High efficacy in combination therapy of GLPG0187 and standard-of-care treatments. (A-C) GLPG0187 combined with the
antiresorptive standard-of-care agent zoledronate in the MDA-MB-231-mouse bone metastasis model (Figure 6) shows efficacy on the tumor
burden, tumor-induced osteolysis, and tibiae bone volume/trabecular bone volume (BV/TV) parameter measured by micro computed tomography
(Μct). (D-F) GLPG0187 combined with the chemotherapeutic standard-of-care agent paclitaxel in the bone metastasis model shows efficacy on
the tumor burden, tumor-induced osteolysis, and tibiae BV/TV parameter measured by μCT. Relevant doses of standard-of-care therapeutic agents
were administered: zoledronate (30 μg/kg weekly subcutaneaously) , paclitaxel (20 mg/kg weekly intraperitoneally). GLPG0187 was tested at 10,
30 and 100 mg/kg, orally, twice daily either separately or in combination with the above therapeutic agents.
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TGF-β-induced EMTand inflammation associated with fi-
brosis, metastasis and cancer [51-54].
Integrin-mediated signaling can enhance cell survival
through several mechanisms. These include regulation of the
expression of BCL-2 [55], FLIP [56], or survival-promoting
pathways such as PI3K-AKT [57] or nuclear factor κB
(NF-κB) signaling [58]. Our findings showed that αv integrin
knockdown does not significantly enhance apoptosis in the
two breast cancer cell lines studied. This might be explained
by the fact that we were targeting a single integrin, and did
not fully disrupt integrin-mediated cell survival.
Integrins are appealing therapeutic targets because
they are expressed in various cell types involved in
tumor progression, and interact with growth factor re-
ceptors. Several preclinical studies have shown that in-
tegrin antagonists inhibit tumor growth by affecting
both tumor cells and tumor-associated host cells (that
is, the angiogenic endothelium). Here we assessed the
effect of a new non-peptide integrin-specific antagonist,
GLPG0187, on breast cancer progression. Administration
of GLPG0187 resulted in a decrease of tumor invasion in
the zebrafish embryo model. Furthermore, GLPG0187 ef-
fectively inhibited the progression of established bonemetastasis in a mouse model of breast cancer and showed
superior activity when combined with antiresorptive and
chemotherapeutic standard-of-care agents. It should be
noted that genetic depletion and pharmacological inhib-
ition represent two different approaches to inhibit αv in-
tegrin function.
Demonstrating that GLPG0187 inhibits bone metastasis
in mice is not sufficient to conclude that the αv integrins
on tumor cells are targeted and responsible for the ob-
served effect. This inhibitor acts in a non cell-autonomous
manner and also selectively inhibits the interaction of αv
integrins of non-tumor cells, for example, stromal cells with
extracellular matrix components [19]. Additional studies in
which, for example, the effect of genetic depletion of αv in-
tegrin in tumor cells on bone metastasis is analyzed, are
needed to directly implicate αv integrin effects on tumor
cells in the bone metastatic response. The (dose-dependent)
selectivity spectra of shRNA-mediated depletion of the total
protein and pharmacological inhibition with GLPG0187
can also be different. For instance, responses that are initi-
ated upon αv integrin activation might be subject to differ-
ent thresholds of signaling intensity/duration. Functions of
αv integrin that are not dependent on its interaction with
the ECM may not be affected by GLPG0187, but will be
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different approaches to address the functional role of αv
integrin in breast cancer cells complement and strengthen
each other.
Conclusions
Here we demonstrate that αv integrin is required for breast
cancer cell invasion and metastasis by regulating mesen-
chymal markers expression and crosstalk with TGF-β sig-
naling. We translate findings obtained in cell culture and
an innovative cost effective and rapid zebrafish xenograft
model to an in vivo mouse model. More specifically, the αv
integrin small molecule antagonist GLPG0187 inhibited
bone metastasis, and maximum efficacy was achieved
when combined with antiresorptive zoledronate or chemo-
therapeutic paclitaxel. An important issue concerning the
interpretation of efficacy of GLPG0187 is that with this ap-
proach we cannot exclude possible effects through target-
ing of integrins on other cell types than the tumor cells,
including cells in the metastatic niche or in the vasculature
[19]. In bone metastasis the activity of osteoclasts is im-
portant for bone resorption, a process that can be inhibited
by targeting integrins. Various integrins, including αvβ3,
have been implicated in tumor angiogenesis. Taken to-
gether, our data suggest that breast cancer patients with
high levels of αv integrin will most likely benefit from a
combinatorial pharmacological approach that includes αv
integrin targeting.
Additional files
Additional file 1: Figure S1. Proliferation of αv integrin deficient
MDA-MB-231 cells in zebrafish. (A) qPCR analysis of MDA-MB-231 cells
and MCF10A-M4 cells. mRNA levels of αv were normalized to GAPDH
expression. (B) Embryos were injected with control shRNA or αv integrin
knockdown MDA-MB-231 cells and examined by fluorescence microscopy
at 1 and 6 days post implantation (dpi) (one representative of 15 embryos is
shown; scale bar: 200 μm). (C) Relative average tumor cell volume at 1 and
6 dpi. (D) Ki67 positive proliferating breast tumor cells at the primary
xenografted site at 6 dpi. Green: Fli-1 GFP, blue: Ki67, red: mCherry-MDA-MB-
231 cells, scale bar: 100 μm.
Additional file 2: Figure S2. Inhibition of tumor progression in
zebrafish by siRNA-mediated knockdown of αv integrin. (A) fli1:GFP
Casper zebrafish were injected with mCherry-labeled MDA-MB-231 cells
transfected with control siRNA or αv integrin knockdown siRNA. Confocal
images were photographed at 6 days post implantation (dpi). Arrows
indicate invasive tumor cells, scale bar: 500 μm. (B) Percentage of
embryos displaying invasion and metastasis at day 6 post-injection. Data
are representative of two independent experiments (each, n >50). C.
High-resolution images of the posterior tail to visualize single metastatic
tumor cells (upper panel, fluorescence; lower panel, transmitted). Arrows
indicate invasive tumor cells, scale bar: 100 μm.
Additional file 3: Figure S3. Stable knockdown of αv integrin in
MCF10A-M4 cells. (A) Representative images of MCF10A-M4 cells
infected with lentivirus expressing control-shRNA or αv integrin
knockdown shRNAs. (B) mRNA level of αv integrin in control and αv
integrin knockdown MCF10A-M4 cells detected by quantitative PCR.
(C) Representative Fluorescence-activated cell sorting (FACS) profiles
of propidium iodine-stained control M4 cells, αv integrin KD 1 and 2
MCF10A-M4 cells and as positive apoptotic control doxorubicintreated MCF10A-M4 cells (Co.Pos). P2: subG1 cells. (D) Percentage of
sub G1 cells calculated by FACS. Average ± standard deviation of 3
independent experiments).
Additional file 4: Figure S4. Effects of αv integrin on mesenchymal
markers. A. mRNA expression of mesenchymal makers in control siRNA or
αv integrin siRNA transfected MDA-MB-231 cells. The mRNA levels of αv
integrin, N-Cadherin, Slug, Snail and Vimentin are normalized to GAPDH
expression. P-values were calculated by the two-sided Student t-test.
(B) Quantitative PCR analysis of Snail mRNA in control and αv integrin
knockdown MDA-MB-231 cells. The RNA levels (± SD) of Snail are
normalized to GAPDH expression. (C) Oncomine™ box plots of αv integrin
and Snail expression levels in normal breast and invasive breast
carcinoma [38].
Additional file 5: Figure S5. Effect of genetic depletion of αv integrin
on expression of transforming growth factor (TGF)-β pathway components
and effect of GLPG0187 on cell proliferation/viability in MDA-MB-231 cells.
(A) Western blot analysis of total and phosphorylated p38 in control and αv
integrin knockdown MDA-MB-231 cells with or without 5 ng/ml TGF-β for
2 h. (B) Immunoblot analysis of phosphorylated Smad2 and 3, total Smad2
and 3, Smad4, TGF-β receptors in MDA-MB-231 αv integrin knockdown cells.
(C) Analysis of the TGF-β-induced Smad3 transcriptional response: 293 T
cells were transfected with the CAGA12-Luc transcriptional reporter, control
siRNA or αv siRNA. Cells were treated with or without 5 ng/ml TGF-β for
16 h. (D) Proliferation curves of MDA-MB-231 cells upon treatment with
vehicle, 0.5, 1 or 10 ng/ml GLPG0187 for 36, 72 and 108 h.
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